Kissei Enters Development and Sales Agreement with Pneuma Partners LLC on Calfactant.
Kissei will attempt to get an early approval of Calfactant for the indication of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) utilizing the results of phase III clinical trial which will be conducted by Pneuma in the US.
ALI and its severe form, ARDS, are types of lung failures resulting from pneumonia, pulmonary injury, etc. There is no effective therapeutic medication for ARDS at present. About 40,000 patients are affected with ALI/ARDS every year in Japan and 30-40% of those patients pass away despite the very best care in the ICU.
JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Jan 15, 2008|
|Previous Article:||Novartis Pharma, Mitsubishi Tanabe Pharma Revise Cooperation HMG-GoA Reductase Inhibitor Lochol(R).|
|Next Article:||Komatsu to Deliver Autonomous Haulage System, Flagship 930E-4 to Rio Tinto.|